CRISPR Therapeutics AG Shareholders Approve Key Proposals

Crispr Therapeutics AG ( (CRSP) ) has shared an update.

On June 5, 2025, CRISPR Therapeutics AG held its Annual General Meeting where shareholders approved several key proposals, including amendments to the company’s Articles of Association, financial statements for 2024, and the re-election of board members and auditors. These decisions, effective upon registration, are expected to strengthen the company’s governance and operational framework, potentially enhancing its strategic positioning in the biotechnology sector.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Spark’s Take on CRSP Stock

According to Spark, TipRanks’ AI Analyst, CRSP is a Neutral.

Crispr Therapeutics AG’s overall stock score reflects financial challenges and valuation concerns, offset by positive technical indicators and a promising partnership with Sirius Therapeutics. The combination of operational difficulties and strategic collaborations suggests a mixed outlook, with potential upside if financial performance improves.

To see Spark’s full report on CRSP stock, click here.

More about Crispr Therapeutics AG

CRISPR Therapeutics AG operates in the biotechnology industry, focusing on the development of transformative gene-based medicines. The company is known for its work in gene editing technologies, particularly using CRISPR/Cas9 technology, with a market focus on treating serious diseases.

Average Trading Volume: 2,102,157

Technical Sentiment Signal: Sell

Current Market Cap: $3.62B

Learn more about CRSP stock on TipRanks’ Stock Analysis page.